HealthEquity, Inc. (HQY) shares rose 1.3% to $93.05 as of October 9, 2026, a modest gain from the prior close of $91.90. BestStocks flagged the session as a major change for HQY. The move is tied to company news. Below, we break down what changed for HQY, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
Company News
HealthEquity appointed Moody's CFO Noémie Heuland to its board of directors. Adds financial expertise and institutional credibility; signals potential strategic or operational refinements ahead.
This summary describes the catalyst and move as first detected on Sep 30, 2026, 5:00 PM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
NewsWeak confidence
Rel. volume
0.9×
Below Avg
Vs peers
—
No comparable peers
Market cap
$7.8B
NASDAQ Global Select
Analyst target
$117
+25.7% vs price
Price chart
Sep 8 – Oct 9
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for HealthEquity, Inc. investors
For HealthEquity, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 1.3% session move; HealthEquity, Inc. (HQY) moved +3.81% from $95.07 to $98.69 on 2026-07-16, reaching a new 30-day high. Weighing against that: HealthEquity, Inc. moved -2.70% intraday from $94.52 to $91.97; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $117.00, implying +25.7% upside from $93.05. BestStocks rates the overall signal quality weak (38/100). With earnings roughly 54 days out, the next report is the most likely near-term test of the move.
HQY price reaction
HQY last traded at $93.05, up $1.15 (+1.25%) from the previous close of $91.90. The session traded on 0.9× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $87.25 and $96.51, and it currently sits about 63% of the way up that band.
Bullish and bearish analyst opinions on HealthEquity, Inc. (HQY)
The consensus analyst price target on HealthEquity, Inc. (HQY) is $117.00, 25.7% above the recent $93.05. Over the past 90 days analysts logged 0 upgrades, 4 maintains, and 0 downgrades. Here is how the bullish and bearish cases on HQY line up.
▲ The bullish case
+Wall Street's consensus price target of $117.00 implies +25.7% upside from $93.05.
+The Street's most bullish target is $142.00 (+52.6%).
+Positive 1.3% session move.
+HealthEquity, Inc. (HQY) moved +3.81% from $95.07 to $98.69 on 2026-07-16, reaching a new 30-day high.
▼ The bearish case
−HealthEquity, Inc. moved -2.70% intraday from $94.52 to $91.97.
−HealthEquity, Inc. (HQY) moved −2.28% from $95.54 to $93.36 on September 8, 2026.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 9, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
HealthEquity, Inc. moved -2.55% intraday from $88.44 to $86.19. HealthEquity, Inc. (HQY) is down about 2.7% to $86.02 amid general market pressure and continued digestion of its late-August post-earnings pullback. ### 📉 Market & Price Action - Intraday dip: Down 2.74% to $86.02 from a prior close of $88.44. - No fresh negative catalysts: There are no new company-specific adverse announcements or SEC filings today. - Extended valuation digestion: The stock continues to feel residual pressure from its late August "sell-the-beat" reaction following Q2 fiscal 2027 earnings, where raised guidance merely matched lofty Wall Street expectations rather than exceeding them. ### 💡 Underlying Context - Strong fundamentals: Management recently reported record HSA assets of $37.9 billion and completed a major share repurchase program. - Analyst backing: Major firms like Barclays and Wells Fargo maintain positive ratings and price targets well above current trading levels ($112+ consensus), viewing the recent downward drift as a potential consolidation phase rather than a structural decline. If you are evaluating HealthEquity (HQY) as a buy, tell me: - Your investment time horizon (short-term vs. long-term) - Whether you are looking for entry points or exit
HealthEquity, Inc. moved -2.21% intraday from $90.39 to $88.39. HealthEquity (HQY ) stock is seeing minor, routine market fluctuations rather than a major sell-off, digesting macroeconomic trends and normal consolidation following its late-August earnings report. ### 📊 Context & Recent Drivers - 📅 Post-Earnings Consolidation: Shares previously pulled back from near 52-week highs after fiscal Q2 results met rather than dramatically exceeded high Wall Street expectations. - 💡 Valuation & Sentiment: Analysts maintain a general "Buy" consensus with an average price target significantly above current trading levels. - ⚠️ Minor Headwinds: General market rotation and light institutional position adjustments have kept the stock range-bound. If you're tracking a specific price movement or options expiry today, let me know your time horizon or cost basis so I can provide more tailored context.
HealthEquity, Inc. moved -2.70% intraday from $94.52 to $91.97. HealthEquity (HQY ) is experiencing downward pressure following its late-August fiscal Q2 earnings release, where a modest earnings beat and inline guidance failed to support its elevated valuation. ### 📊 Valuation & Earnings Context - ⚠️ Sell-the-Beat Reaction : Q2 revenue and EPS topped estimates, but the modest beat underwhelmed a stock trading near its 52-week high. - 📉 Guidance Ceiling : Raised full-year guidance matched Wall Street's optimistic consensus instead of exceeding it. - 📌 Price Multiple : HQY trades at an elevated P/E ratio near 34x, leading investors to lock in profits and digest the recent run-up. If you'd like, let me know: - Your investment timeframe (short-term vs. long-term) - Whether you currently hold shares or are looking to buy the dip I can help you evaluate HQY's risk-reward profile or look at technical support levels.
Activity2026-09-08-2.8%
HealthEquity, Inc. (HQY) moved −2.28% from $95.54 to $93.36 on September 8, 2026. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move appears to be technical; HQY reached a new 30-day low on the day, with volume near its 5-day average.
Material / Earnings2026-08-28+3.2%
HealthEquity, Inc. (HQY) moved +2.94% from $93.62 to $96.37 on 2026-08-28. We checked news, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 2.0x the 5-day average, suggesting modest accumulation ahead of the upcoming earnings report.
In-depth HQY event analyses
Permanent, dated analyses of HQY's most significant sessions.
HQY rose 1.3% to $93.05. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did HQY stock rise?
HQY gained 1.25% ($1.15) versus the prior close of $91.90, last trading at $93.05 on 0.9× average volume.
When is HealthEquity, Inc.'s next earnings date?
HQY's next earnings report is estimated for 2026-12-02 — about 54 days away.
What is the analyst price target for HQY?
The consensus analyst price target for HQY is $117.00, about 25.7% above the current $93.05. Over the past 90 days, analysts recorded 0 upgrades, 4 maintains, and 0 downgrades.
How BestStocks tracks HQY
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for HQY, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 9, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
